In NSCLC, immune checkpoint inhibitors (ICIs), a common type of immunotherapy, also known as biologic treatment, have shown clinical success.[7] The 2 main classes of ICIs are programmed death-ligand 1 (PD-(L)1) Inhibitor and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors. Here, CTLA4 is linked to non-small cell lung carcinoma.